rafapress / Shutterstock
Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind low revocation count | Nearly half a million opt-outs registered.
The Unified Patent Court (UPC) may be less than a week old but it is already set to be the latest stage for the long-running dispute between Sanofi and Amgen concerning antibody patents.
As confirmed by lawyers to WIPR, the German division of French drugmaker Sanofi filed a revocation action against the US pharma company before the court’s central division in Munich citing patent number EP 3 666 797.
It marks a new twist in the global litigation waged between the two companies over antibody patents that wound its way to the US Supreme Court last month.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at firstname.lastname@example.org
court, system, patent, UPC, Sanofi, Hogan Lovells, HGF, Simmons & Simmons, litigation, market, actions, revocation, Amgen